Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Naratriptan
Drug ID BADD_D01535
Description Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.
Indications and Usage For the acute treatment of migraine attacks with or without aura in adults.
Marketing Status approved; investigational
ATC Code N02CC02
DrugBank ID DB00952
KEGG ID D08255
MeSH ID C106783
PubChem ID 4440
TTD Drug ID D0T3KI
NDC Product Code 69452-340; 69452-341; 23155-054; 42043-130; 42043-131; 23155-055; 50090-6162; 0054-0278; 0054-0279
UNII QX3KXL1ZA2
Synonyms naratriptan | N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide | GR 85548A | naratriptan hydrochloride | N-methyl-3-(1-methyl-4-piperidyl)indole-5-ethanesulfonamide monohydrochloride | 1H-indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride | Naramig | Amerge | Colatan
Chemical Information
Molecular Formula C17H25N3O2S
CAS Registry Number 121679-13-8
SMILES CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tinnitus04.04.01.002; 17.04.07.004--
Tracheitis22.07.03.009; 11.01.13.007--
Transient ischaemic attack24.04.06.005; 17.08.04.001--
Tremor17.01.06.002--
Ulcer08.03.06.001--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Varicose vein24.10.04.001--Not Available
Vascular purpura01.01.04.007; 24.07.06.011; 23.06.01.008--Not Available
Vasospasm24.04.02.002--Not Available
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Vomiting07.01.07.003--
White blood cell count increased13.01.06.013--Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.030--Not Available
Dermatosis23.03.03.017--Not Available
Hypoacusis04.02.01.006--
Tachyarrhythmia02.03.02.008--Not Available
Upper respiratory tract inflammation22.12.03.034--Not Available
Muscle tightness15.05.03.007--Not Available
Balance disorder17.02.02.007; 08.01.03.081--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Oral pruritus07.05.05.002--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages